Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2013
09/19/2013US20130245071 Multiple ppi dosage form
09/19/2013US20130245070 Compounds for enhancing arginase activity and methods of using same
09/19/2013US20130245069 Formulations and methods for lyophilization and lyophilates provided thereby
09/19/2013US20130245068 Composition comprising benproperine derivatives as active ingredients for preventing and treating angiogenesis-related diseases
09/19/2013US20130245066 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
09/19/2013US20130245060 Novel composition
09/19/2013US20130245059 Use of Tiotropium Salts in the Treatment of Severe Persistent Asthma
09/19/2013US20130245058 Medical product with a particle-free coating releasing an active substance
09/19/2013US20130245057 Methods and compositions for treating or preventing symptoms of hormonal variations
09/19/2013US20130245056 Increasing drug bioavailability in naltrexone therapy
09/19/2013US20130245055 Pharmaceutical Formulation Containing Gelling Agent
09/19/2013US20130245054 Use of binders for manufacturing storage stable formulations
09/19/2013US20130245049 Novel Antiviral Compounds
09/19/2013US20130245047 Compositions for treating cancer-related fatigue and methods of screening thereof
09/19/2013US20130245046 Novel 2-alkynyl-n9-propargyladenine and medicinal use thereof
09/19/2013US20130245045 Selective phosphodiesterase 9a inhibitors as medicaments for improving cognitive processes
09/19/2013US20130245044 Triazolo[4, 5-d] pyramidine derivatives and their use as purine receptor antagonists
09/19/2013US20130245043 Substituted imidazopyrimidin-5(6h)-ones as allosteric modulators of mglur5 receptors
09/19/2013US20130245040 Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
09/19/2013US20130245039 Combination therapy for proliferative disorders
09/19/2013US20130245037 Stabilization of Hypoxia Inducible Factor (HIF) Alpha
09/19/2013US20130245034 Inhibitors Of Histone Deacetylase
09/19/2013US20130245031 Fused heteroaromatic pyrrolidinones
09/19/2013US20130245030 Preparations and methods for ameliorating or reducing presbyopia
09/19/2013US20130245029 Treatment of cancer with tor kinase inhibitors
09/19/2013US20130245027 Treatment of cancer with tor kinase inhibitors
09/19/2013US20130245026 Treatment of cancer with tor kinase inhibitors
09/19/2013US20130245024 Combination of PPARy Agonist and a Dipeptidyl Peptidase-Inhibitor for the Treatment of Diabetes and Obesity
09/19/2013US20130245015 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
09/19/2013US20130245014 Jak kinase modulating compounds and methods of use thereof
09/19/2013US20130245011 Modulators of ATP-Binding Cassette Transporters
09/19/2013US20130245010 Modulators of atp-binding cassette transporters
09/19/2013US20130245002 Triazolopyridine Compounds
09/19/2013US20130245000 Bicyclic gpr119 modulators
09/19/2013US20130244999 Substituted Heterocyclic Compounds
09/19/2013US20130244992 Method of Inhibiting AB-Type Bacterial Toxins and Treatment for Associated Diseases
09/19/2013US20130244991 Use of 3-methoxy-pregnenolone for the preparation of a drug for treating depressive disorders and long-term neurological diseases
09/19/2013US20130244989 Treatment of alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators
09/19/2013US20130244988 Carbonate and carbamate modified forms of glucocorticoids in combination with b2 adrenergic agonists
09/19/2013US20130244987 Compositions and methods for the treatment of skin diseases
09/19/2013US20130244986 Methods of treating skin disorders with caffeic acid analogs
09/19/2013US20130244985 Drug Depots Having Different Release Profiles for Reducing, Preventing or Treating Pain and Inflammation
09/19/2013US20130244981 Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline
09/19/2013US20130244978 Ophthalmic composition
09/19/2013US20130244974 Surgical hydrogel
09/19/2013US20130244973 Combination of polychitosamine and hmg-coa reductase inhibitor for hyperlipidemia
09/19/2013US20130244972 Injectable chitosan mixtures forming hydrogels
09/19/2013US20130244971 Stabilized ophthalmic galactomannan formulations
09/19/2013US20130244969 Prebiotic Formulations and Methods of Use
09/19/2013US20130244967 Sns-595 and methods of using the same
09/19/2013US20130244963 Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
09/19/2013US20130244962 Cysteine protease inhibitors for the treatment of parasitic diseases
09/19/2013US20130244961 Abnormal intraocular pressure treatment
09/19/2013US20130244960 Treatment for Alzheimer's Disease
09/19/2013US20130244959 Composition Containing Styraxlignolide A or the Aglycone Thereof as an Active Ingredient for Preventing or Treating Asthma
09/19/2013US20130244952 Compositions and methods of delivery of pharmacological agents
09/19/2013US20130244951 Treatment of solid tumors with rapamycin derivatives
09/19/2013US20130244950 Combination therapy for chemoresistant cancers
09/19/2013US20130244932 E-prostanoid receptor, ptger3, as a novel anti-diabetic therapeutic target
09/19/2013US20130244929 Bridged lipoglycopeptides that potentiate the activity of beta-lactam antibacterials
09/19/2013US20130243889 Method of treating ear infections
09/19/2013US20130243886 Novel use
09/19/2013US20130243876 Mir-200 family induces mesenchymal-to-epithelial transition (met) in ovarian cancer cells
09/19/2013US20130243875 Threo-dops controlled release formulation
09/19/2013US20130243873 Immunomodulatory compositions
09/19/2013US20130243872 Pharmaceutical composite formulation comprising hmg-coa reductase inhibitor and aspirin
09/19/2013US20130243869 Dosage forms for oral administration and methods of treatment using the same
09/19/2013US20130243868 Novel formulations
09/19/2013US20130243867 Micelle compositions and methods for their use
09/19/2013US20130243865 Antidiabetic Solid Pharmaceutical Compositions
09/19/2013US20130243864 Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
09/19/2013US20130243863 Stable Formulations for Lyophilizing Therapeutic Particles
09/19/2013US20130243861 Press-coated tablets of prednisone
09/19/2013US20130243860 Standardized plant extract, process for obtaining the same and uses thereof
09/19/2013US20130243859 Orally disintegrating tablet
09/19/2013US20130243858 Compound formulations
09/19/2013US20130243857 Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
09/19/2013US20130243854 Novel formulation of indomethacin
09/19/2013US20130243853 Compositions and methods for treating myelofibrosis
09/19/2013US20130243852 Adjuvant compositions and methods of potentiating hdac inhibitors used to treat various diseases
09/19/2013US20130243848 Nanoparticles, nanoparticle delivery methods, and systems of delivery
09/19/2013US20130243847 Activated creatinine and precursors thereof as antibacterial agents, compositions and products containing such agents and use thereof
09/19/2013US20130243845 Nutraceutical chocolate or compound chocolate product
09/19/2013US20130243842 Compositions and methods for treating bone diseases and broken bones
09/19/2013US20130243833 Compressed formulations of ordered mesoporous silicas
09/19/2013US20130243831 Modified pectins, compositions and methods related thereto
09/19/2013US20130243830 Stable Corticosteroid Nanoparticulate Formulations and Methods for the Making and Use thereof
09/19/2013US20130243827 Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
09/19/2013US20130243825 Compositions and methods for the treatment of skin diseases
09/19/2013US20130243823 Methods and products for increasing the rate of healing of tissue wounds
09/19/2013US20130243811 Immunostimulatory oligonucleotides and uses thereof
09/19/2013US20130243797 Composition comprising hydrolysed proteins and oligisaccharides for treating skin diseases
09/19/2013US20130243794 Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses
09/19/2013US20130243790 Methods Of Treating Obesity By Inhibiting Nicotinamide N-Methyl Transferase (NNMT)
09/19/2013US20130243780 Antibody Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Uses Thereof
09/19/2013US20130243756 Methods for Treating Diseases and HSV Using Antibodies to Aminophospholipids
09/19/2013US20130243755 Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes
09/19/2013US20130243754 Heterocyclic compounds and methods of use
09/19/2013US20130243734 Methods and compositions for wound healing
09/19/2013US20130243732 Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
1 ... 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 ... 7860